In a mouse model of AD, Nash and collaborators have confirmed these results: the overexpression of soluble fractalkine reduces tau pathology with a significant reduction of microglial activation and neuronal loss (Nash et al., 2013). The gene discussed is MAPT; the disease is Alzheimer disease.